Efficacy of N-acetylcysteine in the treatment of nicotine dependence: A double-blind placebo-controlled pilot study

European Addiction Research

Volumn 17, Issue 4, 2011, Pages 211-216

  Schmaal, Lianne ^a   Berk, Lotte ^b   Hulstijn, Kai P ^c   Cousijn, Janna ^a,b   Wiers, Reinout W ^b   Van Den Brink, Wim ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Department of Psychology   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

N acetylcysteine; Nicotine dependence, treatment; Smoking

Indexed keywords

ACETYLCYSTEINE; PLACEBO;

ABSTINENCE; ADULT; ARTICLE; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; PILOT STUDY; PRIORITY JOURNAL; RELAPSE; SELF REPORT; SMOKING HABIT; TOBACCO DEPENDENCE; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ACETYLCYSTEINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PILOT PROJECTS; RECURRENCE; SMOKING CESSATION; TOBACCO USE DISORDER; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79956187841     PISSN: 10226877     EISSN: 14219891     Source Type: Journal    
DOI: 10.1159/000327682     Document Type: Article

References (47)

1. Stivoro: Kerncijfers roken in Nederland 2009. Een overzicht van recente Nederlandse basisgegevens over rookgedrag. Den Haag, Stivoro 2010.
2. Agboola S, McNeill A, Coleman T, Bee JL: A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction 2010; 105: 1362-1380.
3. Mills EJ, Wu P, Spurden D, Ebbert JO, Wilson K: Efficacy of pharmacotherapies for short-term smoking abstinence: a systematic review and meta-analysis. Harm Reduct J 2009; 6:25.
4. Calabresi P, Di Filippo M: ACh/dopamine crosstalk in motor control and reward: a cru-cial role for α6-containing nicotinic receptors? Neuron 2008; 60:4-7.
5. Jones S, Sudweeks S, Yakel JL: Nicotinic re-ceptors in the brain: correlating physiology with function. Trends Neurosci 1999; 22: 555-561.
6. Picciotto MR, Caldarone BJ, King SL, Zacha-riou V: Nicotinic receptors in the brain: links between molecular biology and behavior. Neuropsychopharmacology 2000; 22:451-465. (Pubitemid 30145613)
7. Picciotto MR: Nicotine as a modulator of Behavior: beyond the inverted U. Trends Pharmacol Sci 2003; 24:493-499. (Pubitemid 37088175)
8. Mihalak KB, Carroll FI, Luetje CW: Vareni-cline is a partial agonist at α4ß2 and a full agonist at α7 neuronal nicotinic receptors. Mol Pharmacol 2006; 70:801-805. (Pubitemid 44268437)
9. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, et al: Bupropion-a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56: 395-401.
10. Learned-Coughlin SM, Bergstrom M, Savit-cheva I, Ascher J, Schmith VD, Langstrom B: In vivo activity of bupropion at the human dopamine transporter as measured by posi-tron emission tomography. Biol Psychiatry 2003; 54:800-805. (Pubitemid 37205131)
11. Zaniewska M, Przegalinski E, Filip M: Nico-tine dependence-human and animal stud-ies, current pharmacotherapies and future perspectives. Pharmacol Rep 2009; 61: 957-965.
12. Cahill K, Stead LF, Lancaster T: Nicotine re-ceptor partial agonists for smoking cessa-tion. Cochrane Database Syst Rev 2008;3: CD006103.
13. Hughes JR, Stead LF, Lancaster T: Antide-pressants for smoking cessation. Cochrane Database Syst Rev 2007;1:CD000031.
14. Cornish JL, Kalivas PW: Glutamate trans-mission in the nucleus accumbens mediates relapse in cocaine addiction. J Neurosci 2000; 20:RC89.
15. Di Ciano P, Everitt BJ: Dissociable effects of antagonism of NMDA and AMPA/KA re-ceptors in the nucleus accumbens core and shell on cocaine-seeking behavior. Neuro-psychopharmacology 2001; 25: 341-360. (Pubitemid 32777786)
16. McFarland K, Lapish CC, Kalivas PW: Pre-frontal glutamate release into the core of the nucleus accumbens mediates cocaine-in-duced reinstatement of drug-seeking behavior. J Neurosci 2003; 23: 3531-3537. (Pubitemid 36531996)
17. McFarland K, Davidge SB, Lapish CC, Kali-vas PW: Limbic and motor circuitry underly-ing footshock-induced reinstatement of co-caine-seeking behavior. J Neurosci 2004; 24: 1551-1560. (Pubitemid 38240949)
18. Baker DA, McFarland K, Lake RW, Shen H, Tang XC, Toda S, et al: Neuroadaptations in cystine-glutamate exchange underlie co-caine relapse. Nat Neurosci 2003; 6:743-749. (Pubitemid 36792890)
19. Liechti ME, Lhuillier L, Kaupmann K, Mar-kou A: Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence. J Neurosci 2007; 27:9077-9085. (Pubitemid 47312061)
20. Kenny PJ, Gasparini F, Markou A: Group II metabotropic and α-amino-3-hydroxy-5-methyl-4-isoxazole propionate/kainate glu-tamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats. J Pharmacol Exp Ther 2003; 306:1068-1076. (Pubitemid 37025315)
21. Baker DA, McFarland K, Lake RW, Shen H, Toda S, Kalivas PW: N-acetyl cysteine-in-duced blockade of cocaine-induced rein-statement. New York, New York Academy of Sciences, 2003.
22. Zhou W, Kalivas PW: N-acetylcysteine re-duces extinction responding and induces en-during reductions in cue-and heroin-in-duced drug-seeking. Biol Psychiatry 2008; 63:338-340.
23. LaRowe SD, Myrick H, Hedden S, Mardikian P, Saladin M, McRae A, et al: Is cocaine de-sire reduced by N-acetylcysteine? Am J Psychiatry 2007; 164:1115-1117.
24. Grant JE, Kim SW, Odlaug BL: N-acetylcys-teine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry 2007; 62: 652-657. (Pubitemid 47314380)
25. Knackstedt LA, LaRowe S, Mardikian P, Malcolm R, Upadhyaya H, Hedden S, et al: The role of cystine-glutamate exchange in nicotine dependence in rats and humans. Biol Psychiatry 2009; 65:841-845.
26. Gray KM, Watson NL, Carpenter MJ, LaRowe SD: N-acetylcysteine in young mar-ijuana users: an open-label pilot study. Am J Addict 2010; 19: 187-189.
27. LaRowe SD, Mardikian P, Malcolm R Myrick H, Kalivas P, McFarland K, et al: Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict 2006; 15:105-110. (Pubitemid 43207196)
28. Miller LF, Rumack BH: Clinical safety of high oral doses of acetylcysteine. Semin Oncol 1983; 10:76-85. (Pubitemid 13092611)
29. Mardikian PN, LaRowe SD, Hedden S, Kali-vas PW, Malcolm RJ: An open-label trial of N-acetylcysteine for the treatment of co-caine dependence: a pilot study. Prog Neuro-psychopharmacol Biol Psychiatry 2007; 31: 389-394. (Pubitemid 46209420)
30. Sobell LC, Sobell MB: Timeline followback: a technique for assessing self-reported Alcohol consumption; in Litten RZ, Allen J (eds): Measuring Alcohol Consumption: Psycho-social and Biological Methods. New Jersey Humana Press, 1992, pp 41-72.
31. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO: The Fagerström Test for Nicotine Dependence: a revision of the Fa-gerström Tolerance Questionnaire. Br J Addict 1991; 86:1119-1127.
32. Cox LS, Tiffany ST, Christen AG: Evaluation of the brief questionnaire of smoking urges (QSU-Brief) in laboratory and clinical set-tings. Nicotine Tob Res 2001; 3:7-16. (Pubitemid 32611534)
33. Hughes JR, Hatsukami D: Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 1986; 43:289-294. (Pubitemid 16052281)
34. Tiffany ST, Drobes DJ: The development and initial validation of a questionnaire on smoking urges. Br J Addict 1991; 86:1467-1476.
35. Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG: Multi-variate framework of the Brief Question-naire of Smoking Urges. Drug Alcohol De-pend 2007; 90: 234-242. (Pubitemid 47284718)
36. Cohen J: A power primer. Psychol Bull 1992; 112:155-159.
37. Blondal T, Gudmundsson LJ, Olafsdottir I, Gustavsson G, Westin A: Nicotine nasal spray with nicotine patch for smoking cessa-tion: randomised trial with six-year follow-up. BMJ 1999; 318: 285-288.
38. Hays JT, Hurt RD, Rigotti NA, Niaura R Gonzales D, Durcan MJ, et al: Sustained-re-lease bupropion for pharmacologic relapse prevention after smoking cessation: a ran-domized, controlled trial. Ann Intern Med 2001; 135: 423-433. (Pubitemid 32845867)
39. Piasecki TM, Jorenby DE, Smith SS, Fiore MC, Baker TB: Smoking withdrawal dynam-ics. II. Improved tests of withdrawal-relapse relations. J Abnorm Psychol 2003; 112:14-27. (Pubitemid 36249840)
40. McCarthy DE, Piasecki TM, Fiore MC, Ba-ker TB: Life before and after quitting smok-ing: an electronic diary study. J Abnorm Psychol 2006; 115: 454-466. (Pubitemid 44763676)
41. Markou A: Neurobiology of nicotine depen-dence. Philos Trans R Soc Lond B Biol Sci 2008; 363:3159-3168.
42. Hughes JR: Tobacco withdrawal in self-quit-ters. J Consult Clin Psychol 1992; 60:689-697.
43. Shiffman S, Engberg JB, Paty JA, Perz WG, Gnys M, Kassel JD, et al: A day at a time: pre-dicting smoking lapse from daily urge. J Abnorm Psychol 1997; 106:104-116. (Pubitemid 27063196)
44. McClernon FJ, Kozink RV, Lutz AM, Rose JE: 24-Hour smoking abstinence potentiates fMRI-BOLD activation to smoking cues in cerebral cortex and dorsal striatum. Psycho-pharmacology 2009; 204:25-35.
45. Waters AJ, Shiffman S, Sayette MA, Paty JA, Gwaltney CJ, Balabanis MH: Cue-provoked craving and nicotine replacement therapy in smoking cessation. J Consulti Clin Psychol 2004; 72:1136-1143. (Pubitemid 39658546)
46. John U, Meyer C, Hapke U, Rumpf HJ, Schumann A, Adam C, et al: The Fagerström Test for Nicotine Dependence in two adult population samples-potential influence of lifetime amount of tobacco smoked on the degree of dependence. Drug Alcohol Depend 2003; 71: 1-6. (Pubitemid 36734855)
47. Vink JM, Willemsen G, Beem AL, Boomsma DI: The Fagerström Test for Nicotine Depen-dence in a Dutch sample of daily smokers and ex-smokers. Addict Behav 2005; 30: 575-579. (Pubitemid 40249411)